Orforglipron has reached a new European regulatory milestone. On 15 October 2026, the European Medicines Agency’s human medicines committee recommended granting an EU marketing authorisation for Foundayo, an oral GLP-1 medicine for adult weight management and type 2 diabetes. The recommendation was published on 16 October. It is a positive committee opinion, not yet the European Commission’s final authorisation.
For people following developments in diabetes and obesity treatment, the important news is a potential additional tablet option. It is not a reason to stop an existing treatment, assume access is immediate or expect the same result as a trial average.
What has changed, and what has not?
The Committee for Medicinal Products for Human Use, usually called the CHMP, has completed this stage of its assessment and recommended Foundayo for two adult indications. The applicant is Eli Lilly Nederland B.V. The next decision rests with the European Commission. EMA’s Foundayo opinion page sets out the proposed uses and makes clear that the detailed product information will follow an authorisation.
There are three separate questions: whether a medicine receives authorisation, whether it becomes available locally, and whether a health system pays for it. A favourable answer to the first does not settle the other two. No launch date, price or reimbursement entitlement can be promised from this committee opinion.
Who is included in the recommendation?
The proposed weight-management use is alongside a healthy diet and physical activity in adults with an initial body mass index, or BMI, of at least 30. It also covers adults with a BMI from 27 to below 30 who have at least one weight-related health problem, such as high blood pressure, sleep apnoea, prediabetes or type 2 diabetes.
These are the proposed medicine-specific eligibility criteria, not a new definition of overweight for everybody. BMI also does not describe the whole person or replace an individual assessment.
For type 2 diabetes, the recommendation concerns adults whose glucose is insufficiently controlled, alongside diet and activity. The proposed use includes treatment alone when metformin is inappropriate, or use with other diabetes medicines. It is not an announcement of a new treatment for type 1 diabetes or a recommendation for children.
Why an oral GLP-1 option matters
Orforglipron activates the GLP-1 receptor. EMA describes it as a small, non-peptide molecule developed for oral use. A once-daily tablet may be an appealing option for someone who would prefer not to use injections. Preference matters, but the route of administration is only one part of a treatment decision.
Obesity is a chronic disease with biological, environmental and social influences, as the World Health Organization explains. Medication is not a judgement about willpower. Treatment also needs appropriate nutrition, realistic activity and ongoing support. A different formulation does not remove the need to consider tolerability, other medicines, medical history and affordable access.
What do the weight and glucose findings show?
In its public assessment summary, EMA describes two weight-management studies involving 4,740 adults. Across the studies, average weight loss after 72 weeks was about 5% to 11% with orforglipron, compared with about 2% to 2.5% with placebo. The results varied by dose and study population; the studies included people with and without type 2 diabetes.
That range should not be reduced to a claim that everyone loses 11%. It combines different groups and treatment conditions, and describes averages, not a guaranteed outcome for a particular reader.
EMA also assessed four main type 2 diabetes studies involving 3,765 adults, with different background treatments and comparators. HbA1c fell by about 1.2 to 1.9 percentage points with orforglipron across those studies. This is not a single head-to-head estimate against every other diabetes treatment.
HbA1c reflects average glucose over roughly three months, according to the US National Institute of Diabetes and Digestive and Kidney Diseases. A percentage-point change is different from a relative percentage change. For illustration only, a fall from 8% to 7% is one percentage point; it is not a prediction of an individual’s response or their recommended target.
Weight and HbA1c findings also do not, on their own, establish that this medicine prevents heart attacks, protects the kidneys or is the best choice for everyone. Those are distinct clinical questions.
Side effects still matter with a tablet
EMA’s positive opinion identifies nausea, vomiting and diarrhoea among the most common adverse effects. Its news summary says these occurred more often during dose increases and became less frequent over time. This is a summary of common effects, not a complete list of risks or a substitute for the eventual prescribing information.
The formal CHMP opinion says detailed recommendations will appear in the summary of product characteristics after European Commission authorisation. Until then, the committee announcement should not be used as a self-treatment or switching guide. Oral does not mean side-effect-free.
Questions worth taking to a future treatment discussion
- What is the main goal of my treatment: glucose, weight, another health outcome or several goals together?
- How does the evidence apply to my circumstances rather than to the headline average?
- What side effects, medicine interactions and monitoring would need discussion?
- Has a final authorisation been granted where I live, and what are the local access and cost arrangements?
Do not start, stop or change a diabetes or weight-management medicine because of this news. Decisions belong in a discussion with the clinician who knows your history and current treatment.
Does this mean Foundayo is available across Europe now?
No. As of 16 October 2026, the event reported here is the CHMP recommendation. A European Commission decision is still needed, followed by national access arrangements. An EU committee opinion also does not establish regulatory status in the UK, Saudi Arabia or any other jurisdiction.
How does this relate to the earlier orforglipron news?
Our earlier ACHIEVE-2 report explained a particular trial comparison. This is a different development: a recommendation following a regulatory assessment across a broader evidence package. For wider treatment context, see our guide to the 2026 ADA/EASD type 2 diabetes report.
The bottom line
Foundayo’s positive CHMP opinion is a meaningful step towards another oral option for adult diabetes and weight care. The encouraging efficacy findings sit alongside gastrointestinal side effects, individual differences and unresolved local access. The key distinction remains simple: recommended for EU authorisation is not the same as already authorised and available.